Literature DB >> 18797196

COX-2 expression correlates with survival in patients with osteosarcoma lung metastases.

Nidra I Rodriguez1, William Keith Hoots, Nadezhda V Koshkina, Jaime A Morales-Arias, Carola A Arndt, Carrie Y Inwards, Douglas S Hawkins, Mark F Munsell, Eugenie S Kleinerman.   

Abstract

SUMMARY: The purpose of this study was to determine whether a correlation exists between tumor cyclooxygenase (COX)-2 expression and disease-specific survival in patients with osteosarcoma lung metastases. Thirty-six patients diagnosed with osteosarcoma lung metastases between the years 1990 and 2001 were included in this retrospective study. The majority of the patients (72%) presented newly -diagnosed osteosarcoma lung metastases whereas the remaining patients (28%) presented recurrent disease. Clinicopathologic parameters were obtained from patients' clinical records. Tissue samples were obtained at the time of resection of the lung metastases and stained for COX-2 using immunohistochemistry. Samples were graded according to the intensity of COX-2 staining (grade 0: negative, grade 1: very weak, grade 2: weak, grade 3: moderate, and grade 4: strong). COX-2 staining was correlated with disease-specific survival and clinicopathologic parameters using the Jonckheere-Terpstra and the Kruskal-Wallis tests. All patients with grade 3 or 4 COX-2 expression died of osteosarcoma lung metastases. Ten percent of patients with grade 2 COX-2 expression and 29% of patients with grade 1 expression were alive and free of disease at the last follow-up. By contrast, 60% of the patients with grade 0 COX-2 expression were alive and free of disease at the last follow-up. No association between COX-2 expression and clinicopathologic parameters was found. However, COX-2 expression correlated inversely with disease-specific survival in patients with osteosarcoma lung metastases. Our data indicate that COX-2 expression in metastatic osteosarcoma may have prognostic significance.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18797196      PMCID: PMC2771732          DOI: 10.1097/MPH.0b013e31816e238c

Source DB:  PubMed          Journal:  J Pediatr Hematol Oncol        ISSN: 1077-4114            Impact factor:   1.289


  24 in total

Review 1.  The coxibs, selective inhibitors of cyclooxygenase-2.

Authors:  G A FitzGerald; C Patrono
Journal:  N Engl J Med       Date:  2001-08-09       Impact factor: 91.245

2.  Cyclooxygenase-2 expression does not correlate with outcome in osteosarcoma or rhabdomyosarcoma.

Authors:  David S Dickens; Rafal Kozielski; Patrick J Leavey; Charles Timmons; Timothy P Cripe
Journal:  J Pediatr Hematol Oncol       Date:  2003-04       Impact factor: 1.289

Review 3.  Cyclooxygenase-2 and 5-lipoxygenase converging functions on cell proliferation and tumor angiogenesis: implications for cancer therapy.

Authors:  Mario Romano; Joan Claria
Journal:  FASEB J       Date:  2003-11       Impact factor: 5.191

Review 4.  Inhibitors of cyclo-oxygenase 2: a new class of anticancer agents?

Authors:  Giampietro Gasparini; Raffaele Longo; Roberta Sarmiento; Alessandro Morabito
Journal:  Lancet Oncol       Date:  2003-10       Impact factor: 41.316

Review 5.  Signal transduction pathways regulating cyclooxygenase-2 expression: potential molecular targets for chemoprevention.

Authors:  Kyung-Soo Chun; Young-Joon Surh
Journal:  Biochem Pharmacol       Date:  2004-09-15       Impact factor: 5.858

Review 6.  Regulation of the immune response by prostaglandins.

Authors:  J S Goodwin; J Ceuppens
Journal:  J Clin Immunol       Date:  1983-10       Impact factor: 8.317

7.  Neoadjuvant chemotherapy for high-grade central osteosarcoma of the extremity. Histologic response to preoperative chemotherapy correlates with histologic subtype of the tumor.

Authors:  Gaetano Bacci; Franco Bertoni; Alessandra Longhi; Stefano Ferrari; Cristiana Forni; Roberto Biagini; Patrizia Bacchini; Davide Donati; Marco Manfrini; Gabriella Bernini; Stefano Lari
Journal:  Cancer       Date:  2003-06-15       Impact factor: 6.860

8.  Elevated expression of cyclooxygenase-2 is a negative prognostic factor for disease free survival and overall survival in patients with breast carcinoma.

Authors:  Carsten Denkert; Klaus-Jürgen Winzer; Berit-Maria Müller; Wilko Weichert; Sören Pest; Martin Köbel; Glen Kristiansen; Angela Reles; Antje Siegert; Hans Guski; Steffen Hauptmann
Journal:  Cancer       Date:  2003-06-15       Impact factor: 6.860

9.  The cyclooxygenase-2-selective inhibitors rofecoxib and celecoxib prevent colorectal neoplasia occurrence and recurrence.

Authors:  Elham Rahme; Alan N Barkun; Youssef Toubouti; Marc Bardou
Journal:  Gastroenterology       Date:  2003-08       Impact factor: 22.682

10.  Expression of cyclooxygenase-2 in association with clinicopathological prognostic factors and molecular markers in epithelial ovarian cancer.

Authors:  Sang Soo Seo; Yong Sang Song; Dae-hee Kang; In Ae Park; Yung Jue Bang; Soon Beom Kang; Hyo Pyo Lee
Journal:  Gynecol Oncol       Date:  2004-03       Impact factor: 5.482

View more
  19 in total

1.  Letter regarding the article of Jiao G. J. et al. entitled "Prognostic significance of cyclooxygenase-2 in osteosarcoma: a meta-analysis".

Authors:  Shaozhong He; Zhenyu Xiao; Guangxuan Zeng; Longhua Chen
Journal:  Tumour Biol       Date:  2014-05-10

2.  Prognostic significance of cyclooxygenase-2 in osteosarcoma: a meta-analysis.

Authors:  Guangjun Jiao; Tingting Ren; Qunshan Lu; Yifeng Sun; Zhiyuan Lou; Xianbo Peng; Weimin Liang; Wei Guo
Journal:  Tumour Biol       Date:  2013-07-16

3.  Cyclooxygenase-2 overexpression predicts poor survival in patients with high-grade extremity osteosarcoma: a pilot study.

Authors:  Hiroshi Urakawa; Yoshihiro Nishida; Takahiro Naruse; Hiroatsu Nakashima; Naoki Ishiguro
Journal:  Clin Orthop Relat Res       Date:  2009-03-27       Impact factor: 4.176

4.  Reduced expression and prognostic implication of inhibitor of growth 4 in human osteosarcoma.

Authors:  Dahang Zhao; Xiangjie Liu; Yunge Zhang; Zhaoming Ding; Feng Dong; Hongwei Xu; Baoxin Wang; Wenbo Wang
Journal:  Oncol Lett       Date:  2016-03-09       Impact factor: 2.967

5.  A novel immunochemotherapy based on targeting of cyclooxygenase and induction of immunogenic cell death.

Authors:  Haozhe Huang; Yixian Huang; Yuang Chen; Zhangyi Luo; Ziqian Zhang; Runzi Sun; Zhuoya Wan; Jingjing Sun; Binfeng Lu; Lin Zhang; Jing Hu; Song Li
Journal:  Biomaterials       Date:  2021-02-04       Impact factor: 12.479

6.  COX-2 inhibition improves immunotherapy and is associated with decreased numbers of myeloid-derived suppressor cells in mesothelioma. Celecoxib influences MDSC function.

Authors:  Joris D Veltman; Margaretha E H Lambers; Menno van Nimwegen; Rudi W Hendriks; Henk C Hoogsteden; Joachim G J V Aerts; Joost P J J Hegmans
Journal:  BMC Cancer       Date:  2010-08-30       Impact factor: 4.430

Review 7.  Molecular alterations as target for therapy in metastatic osteosarcoma: a review of literature.

Authors:  J PosthumaDeBoer; M A Witlox; G J L Kaspers; B J van Royen
Journal:  Clin Exp Metastasis       Date:  2011-04-02       Impact factor: 5.150

8.  PLA2G16 Expression in Human Osteosarcoma Is Associated with Pulmonary Metastasis and Poor Prognosis.

Authors:  Shoulei Liang; Zhiwu Ren; Xiuxin Han; Jilong Yang; Luling Shan; Lin Li; Binying Wang; Qianyi Zhang; Tianyang Mu; Kexin Chen; Shunbin Xiong; Guowen Wang
Journal:  PLoS One       Date:  2015-05-18       Impact factor: 3.240

9.  Cyclooxygeanse-2 promotes metastasis in osteosarcoma.

Authors:  Liyan Qu; Bing Liu
Journal:  Cancer Cell Int       Date:  2015-07-04       Impact factor: 5.722

10.  Overexpression of cyclooxygenase-2 in malignant peripheral nerve sheath tumor and selective cyclooxygenase-2 inhibitor-induced apoptosis by activating caspases in human malignant peripheral nerve sheath tumor cells.

Authors:  Michiyuki Hakozaki; Takahiro Tajino; Shinichi Konno; Shinichi Kikuchi; Hitoshi Yamada; Michiro Yanagisawa; Jun Nishida; Hiroyuki Nagasawa; Takashi Tsuchiya; Akira Ogose; Masafumi Abe; Hiroshi Hojo
Journal:  PLoS One       Date:  2014-02-06       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.